Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2009 by The University of Hong Kong.
Recruitment status was  Active, not recruiting
Information provided by:
The University of Hong Kong Identifier:
First received: November 12, 2009
Last updated: NA
Last verified: November 2009
History: No changes posted

Patients with chronic hepatitis B and treated with entecavir for over 6 months (with no previous other antiviral treatment) will be invited to participate in this study. They will be eligible if their liver tests are normal and their viral load is undetectable. Patients will be switched to lamivudine treatment to assess whether lamivudine can maintain adequate suppression of the hepatitis B virus after successful treatment with entecavir. Patients will be monitored closely after switching treatment at 1 months and then every 3 monthly. If there is any evidence of increase in viral load then patients will be given the option of changing back to entecavir.

Condition Intervention
Hepatitis B, Chronic
Drug: Entecavir
Drug: Lamivudine

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load

Resource links provided by NLM:

Further study details as provided by The University of Hong Kong:

Primary Outcome Measures:
  • Determine the efficacy of lamivudine therapy in patients with prior entecavir treatment with undetectable viral load [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Determine the chance of lamivudine resistance in patients with prior entecavir treatment with undetectable viral load [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]

Enrollment: 50
Study Start Date: June 2007
Estimated Study Completion Date: July 2010
Estimated Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Entecavir
Ongoing entecavir 0.5mg daily
Drug: Entecavir
Entecavir 0.5mg orally daily
Other Name: Baraclude
Active Comparator: Lamivudine
Switch to lamivudine 100mg daily
Drug: Lamivudine
Lamivudine 100mg orally, daily
Other Name: Zeffix


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with chronic hepatitis B treated with entecavir for 6 months or more
  • Normal ALT
  • Undetectable HBV DNA by Roche Taqman PCR Assay
  • No other previous therapy with nucleoside/nucleotide analogues

Exclusion Criteria:

  • Presence of other liver diseases including hepatitis C co-infection, autoimmune hepatitis , primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic liver disease, and Wilson's disease
  • History of hepatocellular carcinoma
  • History of decompensated liver disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01013272

The University of Hong Kong
Hong Kong, China
Sponsors and Collaborators
The University of Hong Kong
Principal Investigator: James Fung, MBChB The University of Hong Kong
  More Information

No publications provided

Responsible Party: Dr James Fung, University of Hong Kong Identifier: NCT01013272     History of Changes
Other Study ID Numbers: HKUHEP-01
Study First Received: November 12, 2009
Last Updated: November 12, 2009
Health Authority: Hong Kong: Ethics Committee

Keywords provided by The University of Hong Kong:
sequential therapy

Additional relevant MeSH terms:
Hepatitis B, Chronic
DNA Virus Infections
Digestive System Diseases
Hepadnaviridae Infections
Hepatitis B
Hepatitis, Chronic
Hepatitis, Viral, Human
Liver Diseases
Virus Diseases
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Therapeutic Uses processed this record on March 03, 2015